Sharekhan Recommends 5 Pharma Stocks To Buy For Upto 57% Upside: Why Should You Invest In Pharma Stocks?

Aurobindo Pharma (ARV)

Maintaining a Buy rating for Aurobindo Pharma (ARV), with a Target Price of Rs. 875, Sharekhan estimates an upside of 33%. However, Sharekhan revised earnings estimates for ARV down by around 5% for both FY22E and FY23E.

Cipla

Maintaining a Buy rating for Cipla, with a Target Price of Rs. 1,150, Sharekhan estimates an upside of 28%. the company reported a strong Q2FY22 report, and the brokerage firm is expecting healthy results for FY2022E and FY2023E.

Cadila Healthcare

Maintaining a Buy rating for Cadila Healthcare, with a Target Price of Rs. 720, Sharekhan estimates an upside of 57%. the company also reported a healthy report for the Q2FY22, and Sharekhan is estimating a similar growth in the upcoming days.

Ipca Laboratories

Maintaining a Buy rating for Ipca Laboratories, with a Target Price of Rs. 2,675, Sharekhan estimates an upside of 30%. However, the management is expecting near-term challenges for the company’s API business, along with possibilities of a rise in raw material and logistics prices. Sharekhan has downgraded the company’s estimates for FY22E to FY24E by 4%-7%.

Lupin

Maintaining a Buy rating for Lupin, with a Target Price of Rs. 1,210, Sharekhan estimates an upside of 35%. The Q2FY22 results of the company have fallen marginally due to escalating raw material prices. The brokerage firm has revised down the company’s estimates by 8-10% for FY22E/FY23E.